Immunovant, Inc. Stock Nasdaq
Equities
US45258J2015
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 14.41M | Capitalization | 4.13B |
---|---|---|---|---|---|
Net income 2024 * | -250M | Net income 2025 * | -276M | EV / Sales 2024 * | - |
Net cash position 2024 * | 653M | Net cash position 2025 * | 532M | EV / Sales 2025 * | 250 x |
P/E ratio 2024 * |
-15.9
x | P/E ratio 2025 * |
-15.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.43% |
Latest transcript on Immunovant, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 21-10-03 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 19-12-17 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 19-12-17 |
Douglas Hughes
BRD | Director/Board Member | 62 | 19-12-17 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |